<DOC>
	<DOCNO>NCT00974974</DOCNO>
	<brief_summary>This study evaluate safety efficacy IPX066 advance Parkinson 's disease .</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson 's Disease ( ADVANCE-PD ) .</brief_title>
	<detailed_description>A randomized , double-blind , active-control , parallel-group 13-week comparison IPX066 versus regular carbidopa-levodopa ( CD-LD ) . Prior randomization , subject stable regular LD regimen enter 3-week dose-adjustment period IR CD-LD , follow 6-week dose-conversion period IPX066 .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Diagnosed idiopathic PD . 2 . At least 30 year old time PD diagnosis . 3 . Currently treat IR LD ( CDLD benserazideLD ) stable regimen IR LD least 4 week : Requiring total daily IR LD dose least 400 mg Having minimum dose frequency four time per day . 4 . Able differentiate `` '' state `` '' state . 5 . Have predictable `` '' period . 6 . Amantadine , anticholinergic , selective monoamine oxidase ( MAO ) type B inhibitor ( e.g. , selegiline , rasagiline ) dopamine agonist allow long dos regimens stable least 4 week prior Screening therapy intend constant throughout course study . 7 . Agrees use medically acceptable method contraception throughout study 1 month afterward . 1 . Diagnosed atypical Parkinsonism know secondary Parkinsonian syndrome . 2 . Nonresponsive LD therapy . 3 . Prior functional neurosurgical treatment PD ( e.g. , ablation deep brain stimulation ) procedure anticipate study participation . 4 . Received within 4 week plan take participation clinical study : controlledrelease LD product , additional CD ( e.g. , Lodosyn® ) benserazide ( e.g . Serazide® ) , catecholOmethyl transferase inhibitor ( e.g. , entacapone tolcapone ) , nonselective MAO inhibitor , apomorphine , antipsychotic include neuroleptic agent purpose treat psychosis bipolar disorder . 5 . Allergic Yellow Dye # 5 ( tartrazine ) . 6 . History currently active psychosis . 7 . Active prior medical condition peptic ulcer prior surgical ( e.g. , bowel ) procedure would interfere LD absorption . 8 . Active history narrowangle glaucoma . 9 . A history malignant melanoma suspicious undiagnosed skin lesion . 10 . History myocardial infarction residual atrial , nodal , ventricular arrhythmia , upper gastrointestinal hemorrhage , neuroleptic malignant syndrome and/or nontraumatic rhabdomyolysis . 11 . Received investigational medication 4 week prior Screening . 12 . Unable swallow large pill ( e.g. , large vitamin pill ) . 13 . Pregnant breastfeeding . 14 . Subjects unable complete symptom diary .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson 's Disease</keyword>
</DOC>